At RoukenBio, we provide end-to-end drug development services designed to accelerate innovation in immunology, immuno-oncology, and immune-mediated disease. Our expertise in preclinical drug development enables innovative biotechnology companies to generate the functional, mechanistic, and safety data needed to move confidently from discovery to IND submission.
Our consultative and collaborative approach allows us to tackle challenging, complex projects for a global customer base, delivering excellence across various drug modalities and therapeutic fields. We provide industry-leading pre-established methodologies, alongside novel platforms like IndEx-2 or a completely custom approach designed for your specific therapeutic requirements.
From validating a novel target, characterizing a biologic, or assessing immune safety profiles, our drug development solutions are built on scientific insight, collaborative partnership, and uncompromising data quality.
Difficulty doesn’t deter us; it inspires us. Partner with RoukenBio to answer the critical scientific questions at each stage of development. Together, we’ll design and deliver the experimental models that reveal the full therapeutic potential of your molecule. Download our capabilities brochure to explore how our preclinical drug development services can support your program.
As a global pharmaceutical contract research organization, RoukenBio provides drug development services to the vast scientific network worldwide. Our scientific partners are based mainly in the USA—particularly in Massachusetts (Boston, Cambridge) and California (San Francisco and San Diego)—Canada (from Vancouver up to Seattle), the UK, and Europe.
